{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:47:53Z","timestamp":1783774073931,"version":"3.55.0"},"reference-count":111,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T00:00:00Z","timestamp":1523318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Disease Overview<\/jats:title><jats:p>Hodgkin lymphoma (HL) is an uncommon B\u2010cell lymphoid malignancy affecting 8500 new patients annually and representing approximately 10.2% of all lymphomas in the United States.<\/jats:p><\/jats:sec><jats:sec><jats:title>Diagnosis<\/jats:title><jats:p>HL is composed of two distinct disease entities: classical HL and nodular lymphocyte predominant HL. Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte\u2010rich HL are subgroups of classical HL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Risk Stratification<\/jats:title><jats:p>An accurate assessment of the stage of disease in patients with HL is critical for the selection of the appropriate therapy. Prognostic models that identify patients at low or high risk for recurrence, as well as the response to therapy as determined by positron emission tomography scan, are used to optimize therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Risk\u2010Adapted Therapy<\/jats:title><jats:p>Initial therapy for HL patients is based on the histology of the disease, the anatomical stage and the presence of poor prognostic features. Patients with early stage disease are typically treated with combined modality strategies utilizing abbreviated courses of combination chemotherapy followed by involved\u2010field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. Newer agents including brentuximab vedotin are now being incorporated into frontline therapy and these new combinations are becoming a standard of care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Management of Relapsed\/Refractory Disease<\/jats:title><jats:p>High\u2010dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. For patients who fail HDCT with ASCT, brentuximab vedotin, PD\u20101 blockade, nonmyeloablative allogeneic transplant or participation in a clinical trial should be considered.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ajh.25071","type":"journal-article","created":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T14:40:31Z","timestamp":1523371231000},"page":"704-715","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["Hodgkin lymphoma: 2018 update on diagnosis, risk\u2010stratification, and management"],"prefix":"10.1002","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1244-6758","authenticated-orcid":false,"given":"Stephen M.","family":"Ansell","sequence":"first","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,10]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21442"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(96)80018-7"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197702032960504"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/07357909209032768"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199502163320701"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/302608"},{"issue":"1","key":"e_1_2_6_8_1","first-page":"86","article-title":"Epstein\u2010Barr viral DNA in tissues of Hodgkin's disease","volume":"129","author":"Weiss LM","year":"1987","journal-title":"Am J Pathol."},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.1999.1049"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19991112)83:4<481::AID-IJC8>3.0.CO;2-5"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058617"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.7.1758"},{"key":"e_1_2_6_13_1","first-page":"237","volume-title":"World Health Organization (WHO) Classification of Tumours; Pathology & Genetics; Tumours of Haematopoietic and Lymphoid Tissues","author":"Stein H","year":"2001"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.4.1443.004k55_1443_1450"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.4.1495"},{"key":"e_1_2_6_16_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1054\/blre.2002.0190"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282780"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.3994"},{"key":"e_1_2_6_21_1","first-page":"211","article-title":"Hodgkin's disease, lymphocyte predominance type, nodular\u2013further evidence for a B cell derivation. L & H variants of Reed\u2010Sternberg cells express L26, a pan B cell marker","volume":"133","author":"Pinkus GS","year":"1988","journal-title":"Am J Pathol."},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.776"},{"key":"e_1_2_6_23_1","first-page":"266","article-title":"Whole\u2010body positron emission tomography using 18F\u2010fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease","volume":"86","author":"Jerusalem G","year":"2001","journal-title":"Haematologica."},{"issue":"1","key":"e_1_2_6_24_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood.V73.1.47.47","article-title":"Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964\u20131987","volume":"73","author":"Tubiana M","year":"1989","journal-title":"Blood."},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2003.1.225"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392104"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.2.429"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008327127033"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2252"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.6525"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/5.suppl_2.S101"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111961"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.170"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000067"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.023"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8018"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.5807"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1490-5"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408648"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.6394"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.9.1295"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-104-6-739"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199211193272102"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.5.1421"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1638"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.086"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.5.1080"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.5.972"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.9799"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.3239"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.4803"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008294312741"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022473"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8820"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0910"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61940-5"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1100340"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1104576"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1109618"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70341-3"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510093"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.103"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70501-1"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30696-4"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-402792"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-405456"},{"key":"e_1_2_6_68_1","article-title":"German Hodgkin Study Group Phase I trial of doxorubicin, vinblastine, dacarbazine, and lenalidomide (AVD\u2010Rev) for older Hodgkin lymphoma patients","author":"B\u00f6ll B","year":"2013","journal-title":"Blood."},{"key":"e_1_2_6_69_1","first-page":"461","volume-title":"Textbook of Medical Oncology","author":"Horning S.","year":"2000"},{"key":"e_1_2_6_70_1","first-page":"2339","volume-title":"Principles and Practice of Oncology","author":"Diehl V","year":"2001"},{"key":"e_1_2_6_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.2.210"},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.528"},{"key":"e_1_2_6_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.2.467"},{"key":"e_1_2_6_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.4.1280"},{"key":"e_1_2_6_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.222"},{"key":"e_1_2_6_76_1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.V86.2.451.bloodjournal862451","article-title":"High\u2010dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16\u2013213) with or without cisplatin (CBV +\/\u2010 P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy","volume":"86","author":"Reece DE","year":"1995","journal-title":"Blood."},{"key":"e_1_2_6_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.534"},{"key":"e_1_2_6_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.3.580"},{"key":"e_1_2_6_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059242"},{"issue":"11","key":"e_1_2_6_80_1","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1182\/blood.V93.11.3632","article-title":"ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease","volume":"93","author":"Rodriguez J","year":"1999","journal-title":"Blood."},{"key":"e_1_2_6_81_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008283909959"},{"key":"e_1_2_6_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700838"},{"key":"e_1_2_6_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92411-L"},{"key":"e_1_2_6_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"e_1_2_6_85_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.18"},{"key":"e_1_2_6_86_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008343823292"},{"key":"e_1_2_6_87_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2003.10.018"},{"key":"e_1_2_6_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60165-9"},{"key":"e_1_2_6_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704214"},{"key":"e_1_2_6_90_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609054778"},{"key":"e_1_2_6_91_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.13.2615"},{"key":"e_1_2_6_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-11-0107"},{"key":"e_1_2_6_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2644"},{"key":"e_1_2_6_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V101.2.420"},{"key":"e_1_2_6_95_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"e_1_2_6_96_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"e_1_2_6_97_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3467"},{"key":"e_1_2_6_98_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"e_1_2_6_99_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"e_1_2_6_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"e_1_2_6_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761346"},{"key":"e_1_2_6_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-738385"},{"key":"e_1_2_6_103_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.1350"},{"key":"e_1_2_6_104_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm800251w"},{"key":"e_1_2_6_105_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-2026"},{"key":"e_1_2_6_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70265-0"},{"key":"e_1_2_6_107_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2664"},{"key":"e_1_2_6_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.245"},{"key":"e_1_2_6_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1902"},{"key":"e_1_2_6_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386763"},{"key":"e_1_2_6_111_1","doi-asserted-by":"crossref","unstructured":"JohnstonPB Pinter\u2010BrownL RogerioJ WarsiG ChauQ RamchandrenR.Everolimus for Relapsed\/Refractory Classical Hodgkin Lymphoma: Multicenter Open\u2010Label Single\u2010Arm Phase 2 Study. 54th ASH Annual Meeting.2012;Abstract 2740","DOI":"10.1182\/blood.V120.21.2740.2740"},{"key":"e_1_2_6_112_1","doi-asserted-by":"crossref","unstructured":"Forero\u2010TorresA BarrPM DiefenbachCS et al. A phase 1 study of INCB040093 a PI3K\u03b4 inhibitor alone or in combination with INCB039110 a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r\/r) classical Hodgkin lymphoma (cHL). Paper presented at: 51st ASCO Annual Meeting.2015; Abstract 8558","DOI":"10.1200\/jco.2015.33.15_suppl.8558"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.25071","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T04:05:40Z","timestamp":1694318740000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.25071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,10]]},"references-count":111,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1002\/ajh.25071"],"URL":"https:\/\/doi.org\/10.1002\/ajh.25071","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,10]]},"assertion":[{"value":"2018-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}